Clinical Observation Of Metformin In Treatment Of Patients With Polycystic Ovary Syndrome And Insulin Resistance

Objective To study the effects of metformiii on treating patients with polycystic ovary syndrome (PCOS) and insulin resistance (IR).Methods 30 patients with PCOS and IR were selected as study group and 30 normal women as control group. The clinical symptoms, reproductive hormones, serum glucose and insulin levels were observed. At the end of 12-week therapy with metformin, subjects were re-evaluated and above parameters were measured in study group.Results The study group had markedly higher levels in body mass index (BMI), waist/hip ratio (WHR),Ferrimen-Gallwey score (F-G score), luteinizing hormone (LH), luteinizing hormone /follicle stimulating hormone (LH/FSH), testosterone (T), free testosterone (FT), androstenedione (A2), dihydroepiandrosterone sulfate (DHEAS), fasting blood-glucose (FBG), fasting insulin (FINS), insulin resistance homa model (Homa IR), Homa (3 cell, area under curve glucose (AUCg), area under curve insulin (AUCI) than the control group (P<0.001 0.05). The study group had markedly lower levels in sex hormone binding globulin (SHBG), insulin growth factor binding protein-1 (IGFBP-1), insulin sensitivity index (ISI) than the control group (P< 0.05). The others were not significantly different between two groups. After administration of metformin for 12 weeks in the study group, 22 of 30 (73%) cases recovered ovulation and 4 of 30 (13%) cases obtained pregnancy. BMI, WHR, F-G score, LH, LH/FSH, T, FT, A₂, DHEAS, FINS, Homa IR, Homa p cell, AUCg, AUCI were decreased significantly (P<0.01 0.05) and SHBG, IGFBP-1, ISI were increased significantly after treatment (P< 0.05). No difference was found in others.Conclusion Metformin may effectively improve IR, reduce serum androgen levels, and recover ovulation in patients with PCOS and IR.